📖 This weekend don't miss our KIReports #ISNFridaySelection: Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial kireports.org/article/S2468-…

💥As Women in Nephrology-India Women In Nephrology, we are frequently asked lots of questions concerning parenthood in kidney failure. ⚡I hope my latest VA addresses many of them Check it out👇👇👇 Shilpa Jesudason et al. Int Society of Nephrology ISN Education Fernanda Arce-Amaré

💥Recently approved antibiotics ⚠️Need to use appropriately ‼️ #ISNFrontiers ISN Education Int Society of Nephrology Indian Society of Nephrology Vivekanand Jha | विवेकानन्द झा

💥Recently approved antibiotics for UTI 👉Ceftazidime-avibactam 👉Ceftolozane-tazobactam 👉Meropenem-vaborbactam 👉Cefiderocol 👉Fosfomycin 👉Plazomicin #ISNFrontiers ISN Education Int Society of Nephrology Indian Society of Nephrology Vivekanand Jha | विवेकानन्द झा

See the new Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and KDIGO diabetesjournals.org/care/article-a… Steno Diabetes Center Copenhagen KDIGO george bakris Ian de Boer American Diabetes Association - DiabetesPro

➡️ Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial kireports.org/article/S2468-…

⚡️Original research: A comparative study of recipients' outcomes receiving a kidney from the same deceased donor: An observational study Dr Prof Manisha Sahay Kiranmai Ismal Dr P S Vali Samuel Palli Swarnalatha Guditi

BGRS .Something new I learnt today #ECNeph

SGLT2 inhibitors reduce CKD progression by ~40%, regardless of: - Diabetes - CKD aetiology - Type of glomerular disease And reduces AKI by ~20% Presented by Natalie Staplin on behalf of Oxford Population Health (OxPop) Renal Studies Group & SGLT2 Trialists Consortium (SMART-C) #KidneyWk

EMPA KIDNEY results in NEJM on 4/11/2022

Oral Tebipenem is equivalent to IV Ertapenem in this study. Would just like to know how Faropenem fares in this regard. #nephtwitter nejm.org/doi/full/10.10…

Autosomal Dominant #Tubulointerstitial Kidney Disease: An Emerging Cause of Genetic #CKD doi.org/10.1016/j.ekir… #KIRReview

Let’s talk membranous nephropathy: Autoimmune (IgG) response to antigen (Ag) forming IgG-Ag immune complexes along subepithelial region of glomerular base membranes (GBM), along with massive podocyte injury with ensuing proteinuria. 1/10

Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D 🔓bit.ly/3Zooshy ➡️DOAC treatment, compared to warfarin, is associated with almost 30% lower risk of bleeding in patients with NVAF and CKD G3-G5D.

Dr Deepak Ray of Rabindranath Tagore Hospital Kolkata presents his modified protocol for ABOi #kidney #transplant as a strategy to reduce infections, at the #ISNSCCON 2023 in Coimbatore. His paper on this subject 👉 sjkdt.org/article.asp?is…

ADPKD spectrum genes by Dr. Peter Harris. Mayo Clinic Nephrology Mayo Clinic Transplant. It is not only PKD1 or PKD2 anymore.

Targeting the Alternative #Complement Pathway with Iptacopan to Treat #IgANephropathy: Design and Rationale of the #APPLAUSE-IgAN Study #VisualAbstrac by Edgar V. Lerma 🇵🇭 kireports.org/article/S2468-…

SGLT2 inhibitors in CKD ca. 2023 from Kidney Medicine GlomCon Nasim Wiegley, MD, FASN Mythri Shankar 🇮🇳 Ana Kris #Nephpearls 👉🏼 kidneymedicinejournal.org/article/S2590-…

MAIN Trial: Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy - A Randomized Clinical Trial ca. 2023 from JAMA #Nephpearls #NephJC #VisualAbstract by Jeyakumar Meyyappan jamanetwork.com/journals/jaman…

Membranous Nephropathy at GlomCon Fellowship today. What's your flavour- RTX? Modified-modified Ponticelli? Raja Ramachandran (राजा) expertly addresses the nuances of everyday MN practice with current evidence. + practical case workshops w Bhadran Bose, Dr Veena Roberts & Prof Chen Au Peh